The FDA approved a new indication for the use of the osteoporosis medicine, Prolia® (denosumab): “Treatment to increase bone mass in men with osteoporosis at high risk for fracture.”
With this approval five osteoporosis medicines are approved for use in men: Fosamax® (alendronate), Actonel® (risedronate), Reclast® (zoledronic acid), Forteo® (teriparatide), and Prolia® (denosumab).